Diabetes

Diabetes

Diabetes is a disease that occurs when your blood glucose, is too high. Blood glucose is your main source of energy and comes from the food you eat

circle main
image
image image
image
image

Glimpacare Plus®

image

Glimpacare Plus®

GLIMPACARE PLUS, a fixed-dose combination of empagliflozin and linagliptin, is indicated in adults aged I8
years and older with type 2 diabetes mellitus:
- To improve glycemic control when metformin and/or a sulphonylurea (SU) and one of the monocomponent of Glimpacare Plus do not provide adequate glycemic control
- When already being treated with the free combination of empagliflozin and linagliptin.

image

More details

GLIMPACARE PLUS, a fixed-dose combination of empagliflozin and linagliptin, is indicated in adults aged I8
years and older with type 2 diabetes mellitus:
- To improve glycemic control when metformin and/or a sulphonylurea (SU) and one of the monocomponent of Glimpacare Plus do not provide adequate glycemic control
- When already being treated with the free combination of empagliflozin and linagliptin.

Empagliflozin 25 mg

Linagliptin 5 mg

The recommended starting dose is I film-coated tablet of (I 0 mg empagliflozin plus 5 mg linagliptin) once daily.

In patients who tolerate this starting dose and require additional glycaemic control, the dose can be increased to 1

film-coated tablet of Glimpacare Plus (25 mg empagliflozin plus 5 mg linagliptin) once daily.

When Glimpacare Plus is used in combination with a sulphonylurea or with insulin, a lower dose of sulphonylurea or insulin may be considered to reduce the risk of hypoglycemia.

Patients switching from empagliflozin (either 10mg or 25 mg daily dose) and linagliptin (5 mg daily dose) to Glimpacare Plus should receive the same daily dose of empagliflozin and linagliptin in the fixed-dose combination as in separate tablets. The metformin dose should be continued.

 

GLIMPACARE PLUS, fixed-dose combination of empagliflozin and linagliptin, is indicated in adults aged I8

years and older with type 2 diabetes mellitus:

  • To improve glycemic control when metformin and/or a sulphonylurea (SU) and one of the monocomponent of Glimpacare Plus do not provide adequate glycemic control
  • When already being treated with the free combination of empagliflozin and

 

Glimpacare Plus: Carton box containing (AI/transparent colorless PVC) strips, each of I 0 film-coated tablets, and an inner leaflet.

wave map